MedPath

MONASH UNIVERSITY

MONASH UNIVERSITY logo
🇦🇺Australia
Ownership
Private
Established
1958-01-01
Employees
10K
Market Cap
-
Website
https://www.monash.edu/emerging-tech-research-lab

Clinical Trials

532

Active:41
Completed:202

Trial Phases

6 Phases

Early Phase 1:1
Phase 1:10
Phase 2:43
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (493 trials with phase data)• Click on a phase to view related trials

Not Applicable
388 (78.7%)
Phase 2
43 (8.7%)
Phase 4
33 (6.7%)
Phase 3
18 (3.7%)
Phase 1
10 (2.0%)
Early Phase 1
1 (0.2%)

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)

Not Applicable
Recruiting
Conditions
Myeloma
Leukemia
Non Hodgkin's Lymphoma
Interventions
First Posted Date
2025-10-01
Last Posted Date
2025-10-07
Lead Sponsor
Monash University
Target Recruit Count
900
Registration Number
NCT07202091
Locations
🇦🇺

Royal Adelaide Hospital, Adelaide, South Australia, Australia

🇦🇺

Austin Hospital, Melbourne, Victoria, Australia

🇦🇺

Northern Health, Melbourne, Victoria, Australia

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)

Not Applicable
Recruiting
Conditions
Myeloma
Non Hodgkin's Lymphoma
Leukemia
Interventions
First Posted Date
2025-10-01
Last Posted Date
2025-10-07
Lead Sponsor
Monash University
Target Recruit Count
900
Registration Number
NCT07202065
Locations
🇦🇺

Royal Adelaide Hospital, Adelaide, South Australia, Australia

🇦🇺

Austin Hospital, Melbourne, Victoria, Australia

🇦🇺

Northern Health, Melbourne, Victoria, Australia

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

First Posted Date
2025-10-01
Last Posted Date
2025-10-07
Lead Sponsor
Monash University
Target Recruit Count
900
Registration Number
NCT07202052
Locations
🇦🇺

Royal Adelaide Hospital, Adelaide, South Australia, Australia

🇦🇺

Austin Hospital, Melbourne, Victoria, Australia

🇦🇺

Northern Health, Melbourne, Victoria, Australia

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

Not Applicable
Recruiting
Conditions
Myeloma
Non Hodgkin's Lymphoma
Leukemia
Interventions
First Posted Date
2025-10-01
Last Posted Date
2025-10-07
Lead Sponsor
Monash University
Target Recruit Count
900
Registration Number
NCT07202078
Locations
🇦🇺

Royal Adelaide Hospital, Adelaide, South Australia, Australia

🇦🇺

Austin Hospital, Melbourne, Victoria, Australia

🇦🇺

Northern Health, Melbourne, Victoria, Australia

PeRiOperative Medicine Platform Trial

Not Applicable
Not yet recruiting
Conditions
Anaesthesia
Major Complications
Quality of Life
Quality of Recovery (QoR-15)
Surgical Site Infection After Major Surgery
Interventions
Drug: Liberal inspired oxygen
Drug: Conservative inspired oxygen
Drug: Intermediate inspired oxygen
First Posted Date
2025-09-22
Last Posted Date
2025-09-25
Lead Sponsor
Monash University
Target Recruit Count
7800
Registration Number
NCT07186634
Locations
🇦🇺

The Alfred, Melbourne, Victoria, Australia

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 16
  • Next

News

Monash Scientists Decode RNA Splicing Mechanisms, Opening Path to Personalized mRNA Therapies

Monash University researchers have uncovered the genetic code governing how mutations affect RNA splicing, a critical cellular process for protein production.

Immuron Submits IND Application to FDA for Novel C. difficile Therapy IMM-529

Immuron has submitted an Investigational New Drug (IND) application to the FDA for IMM-529, an oral therapy targeting Clostridioides difficile infection (CDI), with Phase 2 trials planned for the first half of 2026.

Monash University Establishes Boston Hub to Accelerate Global Drug Discovery Partnerships

Monash University has established the Monash Boston Hub in Cambridge to deepen collaborations with North American and European biotech companies for drug discovery and health innovations.

Monash University Researchers Develop Entelli-02 Phage Cocktail to Combat Antimicrobial-Resistant Enterobacter Infections

Researchers from Monash University and The Alfred Hospital have developed Entelli-02, a five-phage cocktail specifically designed to target Enterobacter cloacae complex bacteria, which caused over 200,000 deaths globally in 2019.

Percheron Therapeutics Appoints CMO and CTO to Advance HMBD-002 Cancer Immunotherapy Toward Phase II Trial

Percheron Therapeutics has appointed Dr Eugene Kennedy as Chief Medical Officer and Valentina Dubljevic as Chief Technology Officer to strengthen leadership ahead of HMBD-002's phase II trial.

Immuron Reports Record Sales Growth and Advances Multiple Clinical Programs for Infectious Disease Treatments

Immuron achieved record global revenue of $7.3 million in FY2025, representing a 49% increase driven by strong growth in its traveler's diarrhea product Travelan.

Large Real-World Study Questions Effectiveness of Immunoglobulin Replacement Therapy in CLL Patients

A retrospective analysis of 6,217 CLL patients in Australia found that regular immunoglobulin replacement therapy was not associated with reduced risk of serious infections requiring hospitalization.

CEPI Launches Two Major Initiatives to Accelerate Vaccine Development and Regulatory Approval in Disease Outbreaks

CEPI is providing $1 million to the African Vaccine Regulatory Forum (AVAREF) to enhance multi-country clinical trial application reviews, aiming to reduce approval times from 6-18 months to 10-15 days during health emergencies.

Eight Healthy Babies Born in Britain Using Three-Person DNA Technique to Prevent Mitochondrial Disease

Eight healthy babies were born in Britain using an experimental technique that combines DNA from three people to prevent mothers from passing devastating mitochondrial diseases to their children.

Anti-Nausea Drug Aprepitant Shows Significant Survival Benefits in Triple-Negative Breast Cancer

A large observational study of 13,811 women with early-stage breast cancer found that aprepitant, a commonly prescribed anti-nausea medication, was associated with an 11% lower risk of cancer recurrence and 17% lower risk of breast cancer-related death.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.